News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Long‐term Results of Low‐intensity Chemotherapy with Clofarabine or Cladribine Combined with Low‐Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Original Publication Date
Article Source
External Web Content
Abstract Background The treatment of older patients with newly diagnosed acute myeloid leukemia (AML) using intensive chemotherapy is associated with treatment intolerance and poor survival. We evaluated two new lower‐intensity regimens with clofarabine (n=119) or cladribine (n…

RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML

Original Publication Date
Article Source
External Web Content
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory acute myeloid leukemia (AML), according to the results of a phase II trial presented at the 2020 American…

Post-Traumatic Stress Disorder Prevalent in Patients with Acute Myeloid Leukemia

Original Publication Date
Article Source
External Web Content
Patients with acute myeloid leukemia can experience post-traumatic stress disorder (PTSD) one month after receiving intensive chemotherapy and may benefit from supportive approach-oriented coping interventions, according to data published in Cancer. Previously, there have been…

How Mindfulness Meditation Can Help Cancer Survivors Cope with Stress

Original Publication Date
Article Source
External Web Content
Clinical psychologist Jessica Pieczynski, PhD, offers insights into how practicing mindfulness techniques can help cancer survivors manage stress during the pandemic, and beyond. It’s possible that 2020 will go down in history as the year of Murphy’s Law. The whole “what can go…

The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era

Original Publication Date
Article Source
External Web Content
Abstract Introduction Intravenous and subcutaneous hypomethylating agents have held a key role in myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia treatment. Following the approval of the cedazuridine/decitabine combination, ASTX727, as well as…

Yoga in Oncologic Care: An Evidence-Based Treatment to Improve Outcomes

Original Publication Date
Article Source
External Web Content
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Increasingly, patients with cancer desire nonpharmacologic strategies for…

Pegcetacoplan Superior to Eculizumab for Paroxysmal Nocturnal Hemoglobinuria

Original Publication Date
Article Source
External Web Content
Pegcetacoplan was superior to eculizumab in improving outcomes in patients with paroxysmal nocturnal hemoglobinuria (PNH) according to a recent study published in the New England Journal of Medicine. PNH is a rare, acquired hematologic disease that causes fatigue, increased risk…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families